Stocks · Health care · Pharmaceutical Preparations

Generate Biomedicines, Inc.

GENB

United States Fiscal year ends December CIK 0002100782 Results filed 6 Aug 2026

Add to watchlist

By person

7 insiders · 14 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Noubar Afeyan

Director

$150.00M (6)

—

+$150.00M

1,562,500

1.22%

$25.30M

—

Michael Nally

Chief Executive Officer

$240.00K (1)

—

+$240.00K

1,889,361

1.47%

$30.59M

+56.0%

Frances Arnold

Director

—

$200.74K (2) scheduled

−$200.74K

452,535

0.3526%

$7.33M

−2.7%

Jason Silvers

President & CFO

$32.00K (3)

—

+$32.00K

1,000

0.0008%

$16.19K

—

Jane L Mendillo

Director

$24.00K (1)

—

+$24.00K

1,500

0.0012%

$24.29K

—

Beth Grous

Chief People Officer

$4.80K (1)

—

+$4.80K

300

0.0002%

$4.86K

—

Stephane Bancel

Director

—

724,160

0.5642%

$11.73M

—

Generate Biomedicines, Inc.

What the insiders did Net buying

By person